Clinical trials: Prostate Cancer Recurrence After Radical Prostatectomy
Prostate Cancer
Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00002874
- Testing
- bicalutamide, radiation therapy
- Where
- 240 sites in United States, Canada
- Volunteers
- 840 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence
This study is designed to measure the impact of Satraplatin plus radiation therapy to the bed of the prostate in patients who have developed biochemical failure of their prostate cancer.
- Trial name
- NCT00480623
- Testing
- Satraplatin plus radiation therapy
- Where
- 4 sites in United States
- Sponsor
- Agennix
Prostate Cancer
Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer
RATIONALE: Soy protein may help prevent prostate cancer recurrence in patients who have undergone surgery for prostate cancer. PURPOSE: This randomized phase II/III trial is studying how well soy protein works and compares it to…
- Trial name
- NCT00765479
- Testing
- soy protein isolate
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- University of Illinois Chicago
Metastatic Castration Sensitive Prostate Cancer
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
The purpose of this study is to find out what effects, good and/or bad, taking ipilimumab with degarelix before surgery to remove the prostate, followed by more degarelix and ipilimumab after the surgery, will have on prostate…
- Trial name
- NCT02020070
- Testing
- Degarelix, Ipilimumab, Radical Prostatectomy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
All men following Radical Prostatectomy (RP) at NYU Langone Health undergo routine prostate specific antigen (PSA) testing in order to identify disease recurrence.
- Trial name
- NCT05678322
- Testing
- 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent, PET MRI Imaging
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- NYU Langone Health
Recurrent Prostate Cancer
Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy
The study evaluates the prostate-specific antigen (PSA) response in HLA-A*02 positive patients with biochemical recurrence after radical prostatectomy treated with a prostate-specific peptide vaccine in combination with different…
- Trial name
- NCT02452307
- Testing
- Peptide vaccine, Montanide ISA-51, Granulocyte macrophage colony stimulating factor (GM-CSF)
- Volunteers
- 36 people
- Sponsor
- University Hospital Tuebingen
Prostate Cancer
PROvenge Treatment and Early Cancer Treatment
The PROTECT-PROvenge Treatment and Early Cancer Treatment trial was a Phase III trial for patients with hormone sensitive prostate cancer. The study was conducted at over 15 participating centers throughout the US.
- Trial name
- PROTECT (NCT00779402)
- Testing
- Control, Sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 176 people
- Sponsor
- Dendreon
Prostate Cancer (Post Prostatectomy)
Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy
The goal of this clinical trial is to compare 64Cu-SAR-bisPSMA PET/CT and 68Ga PSMA-11 PET/CT in men with biochemical failure following radical prostatectomy.
- Trial name
- Co-PSMA (NCT06907641)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- Australia
- Volunteers
- 50 people
- Sponsor
- St Vincent's Hospital, Sydney
Prostate Cancer
Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer
This study is the first prospective, randomized phase III clinical trial designed to evaluate whether ultrahypofractionated radiotherapy is non-inferior to conventionally moderately hypofractionated radiotherapy in terms of…
- Trial name
- NCT07500701
- Testing
- Moderate hypofractionated radiotherapy (Moderate-hypoRT), Ultra-hypofractionated radiotherapy (Ultra-hypoRT)
- Where
- South Korea
- Volunteers
- 270 people
- Sponsor
- Samsung Medical Center
Prostate Cancer
Evaluation of Post-operative Biochemical Recurrence in Patients Submitted to Radical Prostatectomy Under General Opioid-free Anesthesia Compared to Conventional General Anesthesia
The use of opioids facilitates angiogenesis and has a proven action in the immune system, mainly in the reduction of natural killer cell activity, favoring the migration of neoplastic cells and inhibiting humoral and cellular…
- Trial name
- NCT03212456
- Testing
- opioid-free group, Opioid Group, transversus abdominal plane block with ropivacaine
- Where
- Brazil
- Volunteers
- 146 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Cancer of Prostate
Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP
This is a phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist (arm A) versus anti-androgen therapy (AAT) with…
- Trial name
- SAVE (NCT03899077)
- Testing
- Apalutamide, Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial, Goserelin Acetate 10.8 MG Subcutaneous Implant
- Where
- 9 sites in Belgium
- Volunteers
- 202 people
- Sponsor
- Cancer Research Antwerp
Adenocarcinoma of the Prostate
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
The primary hypothesis of this study is that outcomes for patients with biochemically recurrent prostate cancer following radical prostatectomy will be improved by the addition of enzalutamide for 6-months compared to…
- Trial name
- NCT02203695
- Testing
- Enzalutamide, SRT
- Where
- 9 sites in United States
- Volunteers
- 86 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer Recurrence After Radical Prostatectomy
Targeted Radiotherapy for Recurrent Prostate Cancer
The TASTEPRO pilot trial evaluates the feasibility of PSMA PET-CT (Computer tomography) targeted stereotactic radiation therapy (SABR) in management of lymph node positive prostate cancer recurrence after radical prostatectomy.
- Trial name
- TASTEPRO (NCT05067660)
- Testing
- Stereotactic ablative radiotherapy, Current standard template-based salvage therapy
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Tampere University Hospital
Prostate Cancer
Long-term Better Than Short-term ADT With Salvage RT
A randomized, multicenter, prospective PHASE II trial to assess the effect of short- versus long-term adjuvant ADT with high dose salvage radiotherapy on distant metastasis free survival in case of biochemical relapse (BR) after…
- Trial name
- LOBSTER (NCT04242017)
- Testing
- Triptoreline
- Where
- 3 sites in Belgium
- Volunteers
- 394 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Prostate Cancer Recurrent
Salvage Lymph Node Dissection in Prostate Cancer Patients With Recurrence After Radical Prostatectomy
Despite continuous technical improvements in urologic surgery, up to 40% of prostate cancer patients will develop biochemical recurrence after radical prostatectomy (RP), potentially because of micro metastasis at the time of the…
- Trial name
- NCT02974075
- Testing
- Salvage lymph node dissection
- Where
- Austria
- Volunteers
- 65 people
- Sponsor
- Medical University of Vienna
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy
This early phase I trial studies the feasibility of a daily, long-term intermittent fasting routine in preventing or delaying a rise in prostate specific antigen (PSA) levels in patients with prostate cancer that has not spread…
- Conditions
- Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
- Trial name
- NCT04288336
- Testing
- Food Diary, Preventative Dietary Intervention, Questionnaire Administration
- Where
- United States
- Sponsor
- Mayo Clinic
Prostate Cancer, Biochemical Recurrence
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or SRT combination with ADT in prostate cancer patients with biochemical…
- Trial name
- NCT06305832
- Testing
- Rezvilutamide, Androgen deprivation therapy (ADT), SRT
- Where
- 2 sites in China
- Volunteers
- 102 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
Archive Prostate. Observational Study of Patients Who Underwent Radical Prostatectomy Surgery
This is a single-center, observational, prospective study on quality of life and disease status of patients who underwent radical prostatectomy.
- Trial name
- NCT06154499
- Testing
- Radical prostatectomy
- Where
- Italy
- Volunteers
- 1,784 people
- Sponsor
- IRCCS San Raffaele
Prostate Cancer, Cancer Recurrence
PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy
After radical prostatectomy approximately 15-40% of men develop a biochemical recurrence (BR) within 5 years. The standard treatment of post-prostatectomy BR is salvage external beam radiation therapy (sEBRT).
- Trial name
- PERYTON (NCT04642027)
- Testing
- Conventional sEBRT, Hypofractionated sEBRT
- Where
- 13 sites in Netherlands
- Volunteers
- 538 people
- Sponsor
- University Medical Center Groningen
Prostatic Neoplasm
Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy
Fluciclovine F18 (Axumin) has been demonstrated to provide good delineation of recurrence of prostate cancer after definitive therapies.
- Trial name
- NCT04234399
- Testing
- Fluciclovine PET/CT using a digital PET/CT
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Vermont